StreetInsider.com News Articles

Form SCHEDULE 13G/A Cardiol Therapeutics Filed by: Tejara Capital Ltd

Wed, 23 Sep 2026 12:16:00 -0400

si-local-file:///var/storage/secattach/20260923/27095331.html

Form 6-K Cardiol Therapeutics For: Sep 23

Wed, 23 Sep 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260923/27093062.html

Cardiol Therapeutics expands Phase III MAVERIC trial to 150 patients

Wed, 23 Sep 2026 06:02:38 -0400

Cardiol Therapeutics Inc. (NASDAQ: CRDL) announced Sept. 23 that it has enrolled 110 patients in its Phase III MAVERIC trial, meeting its original enrollment target ahead of its end-of-September guidance.

The MAVERIC trial is a randomized, double-blind, placebo-controlled, multi-center study evaluating CardiolRx™ for reducing the risk of recurrence in patients with recurrent pericarditis. Following a blinded review of patient data, the MAVERIC Steering Committee recommended expanding enrollment to up to 150 patients. The review showed fewer-than-expected recurrences among patients randomized to either CardiolRx™ or placebo.

"A blinded review of events in MAVERIC patients who have been randomized 1:1 to either CardiolRx™ or

Cardiol Therapeutics expands Phase III MAVERIC trial to 150 patients

Wed, 23 Sep 2026 06:02:38 -0400

"A blinded review of events in MAVERIC patients who have been randomized 1:1 to either CardiolRx™ or

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

Wed, 23 Sep 2026 06:00:00 -0400

Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance.
The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-than-expected recurrences—an

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

Wed, 23 Sep 2026 06:00:00 -0400

Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance.
The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-than-expected recurrences—an

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

Wed, 23 Sep 2026 06:00:00 -0400

Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance.
The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-than-expected recurrences—an

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

Wed, 23 Sep 2026 06:00:00 -0400

Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance.
The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-than-expected recurrences—an

Form SUPPL Cardiol Therapeutics

Wed, 16 Sep 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260916/27069592.html

Form F-10/A Cardiol Therapeutics

Wed, 16 Sep 2026 10:14:00 -0400

si-local-file:///var/storage/secattach/20260916/27068775.html

Form 6-K Cardiol Therapeutics For: Sep 16

Wed, 16 Sep 2026 07:37:00 -0400

si-local-file:///var/storage/secattach/20260916/27067465.html

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

Wed, 16 Sep 2026 07:27:00 -0400

Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028.

TORONTO, Sept. 16, 2026 /PRNewswire/

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

Wed, 16 Sep 2026 07:27:00 -0400

Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028.

TORONTO, Sept. 16, 2026 /PRNewswire/

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

Wed, 16 Sep 2026 07:27:00 -0400

Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028.

TORONTO, Sept. 16, 2026 /PRNewswire/

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

Wed, 16 Sep 2026 07:27:00 -0400

Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028.

TORONTO, Sept. 16, 2026 /PRNewswire/

Form 6-K Cardiol Therapeutics For: Sep 14

Tue, 15 Sep 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260915/27060574.html

Form 6-K Cardiol Therapeutics For: Sep 10

Fri, 11 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260911/27050433.html

Form 6-K Cardiol Therapeutics For: Sep 10

Thu, 10 Sep 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260910/27049356.html

Cardiol Therapeutics files $150M shelf prospectus after OSC review

Thu, 10 Sep 2026 17:00:57 -0400

Cardiol Therapeutics Inc. (NASDAQ: CRDL) has filed a preliminary short form base shelf prospectus with Canadian securities regulators and a corresponding registration statement on Form F-10 with the U.S. Securities and Exchange Commission, the company announced Sept. 10, 2026.

The filing would allow Cardiol to offer and sell up to $150 million in securities over a 25-month period once the final prospectus receives a receipt and the registration statement becomes effective. Securities could include Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof. No securities are currently being offered, and the filing does not obligate the company

Cardiol Therapeutics files $150M shelf prospectus after OSC review

Thu, 10 Sep 2026 17:00:57 -0400

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Thu, 10 Sep 2026 17:00:00 -0400

TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada, together with a corresponding registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission (the "SEC") under the U.S./Canada

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Thu, 10 Sep 2026 17:00:00 -0400

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Thu, 10 Sep 2026 17:00:00 -0400

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Thu, 10 Sep 2026 17:00:00 -0400

Form F-X Cardiol Therapeutics Filed by: Cardiol Therapeutics Inc.

Thu, 10 Sep 2026 13:54:00 -0400

si-local-file:///var/storage/secattach/20260910/27047711.html